New MRI Contrast Agent Pinpoints Aggressive Breast Cancer Tumors
Researchers target tumor protein to distinguish slow-growing tumors from more aggressive ones.
Determining if a given cancer tumor is slow-growing or aggressive is important when choosing the right treatment. MRI scans can help doctors identify the location of a tumor, but do not provide much further information.
That may change with the development of a new MRI contrast agent that not only spots breast cancer tumors at early stages, but also differentiates between aggressive and slow-growing types of tumors. The research was published in September in the journal Nature Communications.
Researchers at Case Western University in Ohio modified a commercially available MRI contrast agent called tri-gadolinium nitride metallofullerene by attaching a peptide named ZD2 to its exterior. The peptide specifically sticks to the protein extradomain-B fibronectin, which is found in high concentrations around aggressive tumors in a number of cancers.
In mice with different types of breast cancer, the new contrast agent lit up clearly around all tumors, but was particularly prominent around the more aggressive tumors.
The new contrast agent is safer and more efficient than traditional agents, requiring a smaller dose and easily flushing from the body without accumulating in tissues, the researchers write.
Their next steps are reducing the cost of producing the agent and testing it in human patients.